<DOC>
	<DOC>NCT01783691</DOC>
	<brief_summary>The purpose of this study is to determine the safety, pharmacokinetics, and pharmacodynamics of NKTT120 in adult patients with stable sickle cell disease.</brief_summary>
	<brief_title>Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Age 18 to 50 years Subject has a confirmed diagnosis of HbSS or HbSÎ²0thal Subject has stable SCD defined as not having acute VOC, ACS, or other major SCD associated event during the month prior to enrollment Subject had an SCDrelated VOC or ACS that required hospitalization or treatment in acute care outpatient setting in the month prior to enrollment Subject requires a program of prescheduled regularly administered packed red blood cell (pRBC) transfusions or Subject received a pRBC transfusion in the month prior to enrollment Subject has evidence of latent or active tuberculosis Subject has a major concurrent illness or medical condition Subject is pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Sickle cell disease</keyword>
</DOC>